EXTON, Pa., Feb. 16, 2021 /PRNewswire/ — Spherix Global Insights (“Spherix”) is a hyper-focused market intelligence firm that leverages its own independent data and expertise to provide strategic guidance, which ensures biopharma stakeholders make decisions with confidence. The company focuses exclusively on select, evolving therapy areas in dermatology, gastroenterology, nephrology, neurology, and rheumatology.
Despite the woes that 2020 brought upon businesses both big and small across the globe, Spherix was fortunate to have achieved a banner year:
Jennifer Robinson, Founder and President of Spherix commented, “I am awed by the professionalism, nimbleness, energy, and commitment of the team we have assembled. Their collective desire and ability to serve our clients and truly partner with them to deliver cutting edge insights has translated into yet another year of phenomenal growth. The pandemic disrupted many things, but the culture of ‘work smart, hustle, have fun, and have each other’s backs’ is firmly intact at Spherix.”
In a move that sets the stage for continued success, Spherix has promoted Lynn Price to Vice President, Strategy and Innovation. Previously, Price oversaw the Immune Franchise and was responsible for all projects in dermatology, gastroenterology, and rheumatology. In her new role, Price will work closely with Lauren Schmitt, newly appointed Brand Director, on the successful rollout of Launch Dynamix™, a new service that offers tracking and benchmarking of new market entrants, as well as the expansion of Special Topix™, a service introduced last year which quickly assesses current market events and their impact on specialty practices.
On top of brand enhancements and long-term planning, Price will also work to expand the role of Spherix’s Advisory Board (which is comprised of the top thought leaders within their core specialties) and begin the development of a patient network.
According to Price, “We’ve built something very special at Spherix, and I am so proud of what we have collectively accomplished over the course of 2020. I’m looking forward to shifting some of my focus to higher level strategic initiatives that continue to respond to the industry’s needs, while helping guide Spherix into its next period of growth.”
As for what to expect in 2021, “Expect the same unwavering focus on our core specialties, continued investment in expanding our team in order to offer innovative intelligence solutions, and our absolute passion about providing clients with unparalleled service and smarts. If we do that, achieving awesome financial results will be a layup,” says Robinson.
Learn more about Spherix here.
About Spherix Global Insights
Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.
All company, brand or product names in this document are trademarks of their respective holders.
For more information contact:
Matt Rigney, Senior Marketing Manager
Email: info@spherixglobalinsights.com
www.spherixglobalinsights.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/spherix-global-insights-releases-2020-corporate-highlights-and-shares-outlook-for-2021-301229218.html
SOURCE Spherix Global Insights
Strategic Expansion into Cardio AI-Driven Healthcare SolutionsCollaboration to Enhance Patient-Centered Digital Healthcare TechnologiesWelcomes Key Industry…
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…